Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was devalued by Zacks.com  from a “get” score to a “hold” ranking in a research note issued to financiers on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on finding as well as creating tiny molecule medicine candidates to treat cancer. The Company‘s items under different phases of advancement include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of other equities research analysts additionally lately talked about the business. Noble Financial editioned a “buy” ranking and provided a $11.00 price objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 and set a “buy” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day relocating ordinary cost of $2.90 as well as a two-hundred day moving typical rate of $4.16. The firm has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, covering analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and an adverse net margin of 8,294.27%. The company had income of $0.06 million throughout the quarter, compared to the agreement estimate of $0.06 million. During the same quarter in the previous year, the firm posted ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will publish -1.18 EPS for the current year.

A number of hedge funds have actually recently bought and sold shares of ONTX. GSA Capital Allies LLP purchased a brand-new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Capital Management LP purchased a new position in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP purchased a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and other institutional capitalists have 13.36% of the firm’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the recognition and also development of oncology therapeutics. It concentrates on finding and also establishing little molecule medication candidates to treat cancer. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a totally free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

For more details concerning research offerings from Zacks Investment Research, go to Zacks.com.

This instantaneous news alert was generated by narrative science technology and economic information from Market in order to supply viewers with the fastest as well as most accurate coverage. This tale was evaluated by Market’s editorial team before magazine. 



Prior to you think about Onconova Therapeutics, you’ll wish to hear this.

Market monitors Wall Street’s top-rated and also best performing research analysts as well as the stocks they suggest to their clients each day. Market has actually determined the 5 stocks that cover experts are quietly murmuring to their customers to get now prior to the more comprehensive market catches on … as well as Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics currently has a “Buy” ranking among experts, premier analysts think these 5 stocks are much better buys.

Comments are closed.